Next Article in Journal
Assessment of Food By-Products’ Potential for Simultaneous Binding of Aflatoxin B1 and Zearalenone
Next Article in Special Issue
Bioengineering of Bordetella pertussis Adenylate Cyclase Toxin for Vaccine Development and Other Biotechnological Purposes
Previous Article in Journal
Uremic Vascular Calcification: The Pathogenic Roles and Gastrointestinal Decontamination of Uremic Toxins
Previous Article in Special Issue
Effects of Modification of Light Parameters on the Production of Cryptophycin, Cyanotoxin with Potent Anticancer Activity, in Nostoc sp.
Review

Engineering Botulinum Neurotoxins for Enhanced Therapeutic Applications and Vaccine Development

Toxines Bacteriennes, Institut Pasteur, 75724 Paris, France
*
Author to whom correspondence should be addressed.
Received: 10 November 2020 / Revised: 16 December 2020 / Accepted: 17 December 2020 / Published: 22 December 2020
Botulinum neurotoxins (BoNTs) show increasing therapeutic applications ranging from treatment of locally paralyzed muscles to cosmetic benefits. At first, in the 1970s, BoNT was used for the treatment of strabismus, however, nowadays, BoNT has multiple medical applications including the treatment of muscle hyperactivity such as strabismus, dystonia, movement disorders, hemifacial spasm, essential tremor, tics, cervical dystonia, cerebral palsy, as well as secretory disorders (hyperhidrosis, sialorrhea) and pain syndromes such as chronic migraine. This review summarizes current knowledge related to engineering of botulinum toxins, with particular emphasis on their potential therapeutic applications for pain management and for retargeting to non-neuronal tissues. Advances in molecular biology have resulted in generating modified BoNTs with the potential to act in a variety of disorders, however, in addition to the modifications of well characterized toxinotypes, the diversity of the wild type BoNT toxinotypes or subtypes, provides the basis for innovative BoNT-based therapeutics and research tools. This expanding BoNT superfamily forms the foundation for new toxins candidates in a wider range of therapeutic options. View Full-Text
Keywords: botulinum neurotoxin; Clostridium botulinum; therapeutic application; recombinant toxin; toxin engineering botulinum neurotoxin; Clostridium botulinum; therapeutic application; recombinant toxin; toxin engineering
Show Figures

Figure 1

MDPI and ACS Style

Rasetti-Escargueil, C.; Popoff, M.R. Engineering Botulinum Neurotoxins for Enhanced Therapeutic Applications and Vaccine Development. Toxins 2021, 13, 1. https://0-doi-org.brum.beds.ac.uk/10.3390/toxins13010001

AMA Style

Rasetti-Escargueil C, Popoff MR. Engineering Botulinum Neurotoxins for Enhanced Therapeutic Applications and Vaccine Development. Toxins. 2021; 13(1):1. https://0-doi-org.brum.beds.ac.uk/10.3390/toxins13010001

Chicago/Turabian Style

Rasetti-Escargueil, Christine; Popoff, Michel R. 2021. "Engineering Botulinum Neurotoxins for Enhanced Therapeutic Applications and Vaccine Development" Toxins 13, no. 1: 1. https://0-doi-org.brum.beds.ac.uk/10.3390/toxins13010001

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop